

Prostatype Genomics announces positive preliminary results for primary endpoint in U.S. study with Prostatype®

Prostatype Genomics is pleased to announce that preliminary results from the study conducted in the United States in collaboration with leading institutions shows promising results. Prostatype® is a genomic test designed to improve risk stratification of patients diagnosed with non-metastatic prostate cancer. The study has a diverse patient population, with a significant proportion of African American patients, which is crucial for ensuring the clinical utility of the test in a patient population with multiple ethnicities.

CEO of Prostatype Genomics, Fredrik Rickman, comments:

“We are obviously happy to see that the preliminary study results are positive and are well in line with the results from other studies with Prostatype®, mainly performed in Europe and Asia. The preliminary results indicate that Prostatype® has strong prognostic potential in identifying patients at high risk of disease progression, and that it is equally effective in predicting prostate cancer-specific mortality. Notably, no significant difference was observed in the test’s performance between African American and Caucasian patients, reinforcing the scientific support for the robustness and reliability of Prostatype® across different patient groups. We look forward to the continued collaboration together with the American institutions that we are collaborating with as more and more data become available for further analysis.”

Gerald L. Andriole, MD, Chief Medical Officer of Prostatype Genomics and former Professor and Head of Urology at Washington University in St Louis, comments:

“The primary objective of the study is to investigate Prostatype®’s performance in predicting the risk of prostate cancer-specific mortality in a U.S. patient population with multiple ethnicities. The initial analysis shows promising results, and we look forward to further data analysis that examines the ability of Prostatype® to predict other important prostate cancer endpoints in this population. Our focus now is on further validating and refining the insights from the study ahead of the final analysis, with the goal of improving precision in prostate cancer treatment decisions.”

For more information, please contact:

Fredrik Rickman, CEO Prostatype Genomics AB

Telephone: +46 (0)73 049 77 01

Email: fredrik.rickman@prostatypegenomics.com

About Prostatype Genomics AB

Prostatype® is a genomic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or no-treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institute and is provided by Prostatype Genomics AB.

This information is information that Prostatype Genomics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-03-31 08:30 CEST.